drugset / Trial / NCT05763459

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

NCT05763459

Phase 1 Completed 12 enrolled Calico Life Sciences LLC AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262

Timeline

Start
2023-03-24
Primary completion
2023-05-08
Completion
2023-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-CLS-7262 Unknown
Subject Digoxin Other / unclassified
Subject Rosuvastatin Small molecule

Indications

No indication recorded.